摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(3-甲基哌啶-1-基)丁烷-1-酮 | 53662-16-1

中文名称
1-(3-甲基哌啶-1-基)丁烷-1-酮
中文别名
——
英文名称
1-butyryl (3-methylpiperidine)
英文别名
1-(3-Methylpiperidin-1-yl)butan-1-one
1-(3-甲基哌啶-1-基)丁烷-1-酮化学式
CAS
53662-16-1
化学式
C10H19NO
mdl
MFCD01357039
分子量
169.267
InChiKey
UPYIVMOCCVOGRZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.9
  • 拓扑面积:
    20.3
  • 氢给体数:
    0
  • 氢受体数:
    1

SDS

SDS:f59ae72659a8de62f18ca00aace7a33f
查看

反应信息

  • 作为产物:
    描述:
    丁酸乙酯3-甲基哌啶 以35%的产率得到1-(3-甲基哌啶-1-基)丁烷-1-酮
    参考文献:
    名称:
    Djeghaba, Zeineddine; Deleuze, Herve; Maillard, Bernard, Bulletin des Societes Chimiques Belges, 1995, vol. 104, # 3, p. 161 - 164
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
    申请人:Gibbons Paul
    公开号:US20120190665A1
    公开(公告)日:2012-07-26
    A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 and R 3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
    公式I的化合物、对映异构体、顺反异构体、互变异构体或其药学上可接受的盐,其中R1、R2和R3的定义如本文所述,可用作一种或多种Janus激酶的抑制剂。本文还揭示了一种包括公式I的化合物和药学上可接受的载体、辅料或载体的药物组合物,以及治疗或减轻患者对Janus激酶活性抑制响应的疾病或状况的方法。
  • DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS
    申请人:YAMASHITA Hiroshi
    公开号:US20120028920A1
    公开(公告)日:2012-02-02
    A heterocyclic compound or a salt thereof represented by the formula (1): where R 2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or lower alkenylene group; and R 1 represents an aromatic group or a heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.
    一种由式(1)所表示的杂环化合物或其盐:其中R2代表氢原子或较低的烷基基团;A代表较低的烷基烯基基团;R1代表芳香基团或杂环基团。本发明的化合物具有广泛的治疗精神障碍的光谱,包括中枢神经系统障碍,无副作用且安全性高。
  • Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders
    申请人:Otsuka Pharmaceutical Co., Limited
    公开号:EP2284169A1
    公开(公告)日:2011-02-16
    A heterocyclic compound or a salt thereof represented by the formula (I): where R2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or a lower alkenylene group; and R1 represents a benzene fused heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.
    一种杂环化合物或其盐,由式(I)代表: 其中 R2 代表氢原子或低级烷基;A 代表低级亚烷基或低级亚烯基;R1 代表苯融合杂环基团。本发明的化合物对包括中枢神经系统疾病在内的精神疾病具有治疗范围广、无副作用、安全性高等特点。
  • Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders
    申请人:Otsuka Pharmaceutical Co., Limited
    公开号:EP2287161A1
    公开(公告)日:2011-02-23
    A heterocyclic compound or a salt thereof represented by the formula (I): where R2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or a lower alkenylene group; and R1 represents a heteromonocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.
    一种杂环化合物或其盐,由式(I)代表: 其中 R2 代表氢原子或低级烷基;A 代表低级亚烷基或低级亚烯基;R1 代表杂环基团。本发明的化合物对包括中枢神经系统疾病在内的精神疾病具有治疗范围广、无副作用、安全性高等特点。
  • US8071600B2
    申请人:——
    公开号:US8071600B2
    公开(公告)日:2011-12-06
查看更多